Core Viewpoint - Eli Lilly has demonstrated strong momentum due to its current portfolio and upcoming catalysts, maintaining a bright outlook despite recent market fluctuations [1][2]. Financial Performance - Eli Lilly's tirzepatide, marketed as Mounjaro and Zepbound, is significantly contributing to the company's revenue, generating $24.8 billion in sales through the first nine months of 2025, surpassing Keytruda as the world's best-selling medicine [3][4]. - Analysts project that tirzepatide could achieve nearly $62 billion in sales by 2030, indicating sustained growth potential [4]. Market Position and Competition - Eli Lilly faces increasing competition in the weight management sector, particularly from Novo Nordisk, Amgen, and Pfizer, but has produced superior clinical trial results [6]. - The company is advancing orforglipron, an oral weight loss candidate, which is expected to receive expedited regulatory review, potentially enhancing its market position [7]. - Eli Lilly's retatrutide has shown unprecedented results in weight loss during clinical trials, further solidifying its leadership in the anti-obesity market [8]. Valuation and Growth Potential - Eli Lilly's stock is currently trading at 33 times forward earnings, higher than the healthcare sector average of 18.2, but this premium is justified by its robust revenue and earnings growth [9]. - The company's price/earnings-to-growth ratio stands at 0.98, indicating it may be undervalued relative to its growth prospects [9]. - Overall, Eli Lilly is positioned for excellent near- and mid-term prospects, making it a potentially attractive investment for 2026 and beyond [10].

BREAKING: Stocks Power To Highs With Big Earnings, News Due Today's Spotlight MarketSurge New Year Sale Invest smarter in 2026 with our BEST deal—14 months of MarketSurge for $1,499 ($600 off). Free Investing Podcast Listen to IBD's podcast for new investing tips and trade ideas every week. Subscribe today! Get Market Insights on IBD Live Join IBD Live to watch and discuss the market action in real time with top market analysts. More News Shares of Investor's Business Daily's Medical-Biomed/Biotech industry ...

Key Takeaways JNJ agreed to match U.S. drug prices under Trump's MFN plan and received a tariff exemption.JNJ is advancing a $55B plan to expand U.S. manufacturing, research and technology by early 2029.JNJ is building new U.S. facilities in Pennsylvania and North Carolina, including a $2B biologics plant.Johnson & Johnson (JNJ) recently signed a landmark agreement with the Trump administration to lower drug prices in the United States.Following this deal, JNJ joins several other large-cap pharma companies ...

1月8日，据英国金融时报消息，这项于周三发表在《英国医学杂志》（BMJ）上的分析涵盖了超过9000 名参与者的数据。研究结果进一步证实，对于许多使用Ozempic、Wegovy和Mounjaro等药物的用户而 言，要在停药后维持显著的减重效果及相关的健康红利面临极高难度。数据表明，停药后的体重反弹不 仅普遍，且速度极快，健康指标的恶化甚至早于体重的完全恢复。 报道指出，专家警告称，随着未来几年数以百万计的用户可能停止使用这些热门药物，各国卫生当局亟 需制定应对计划。牛津大学公共卫生营养科学家Susan Jebb指出，肥胖是一种慢性复发性疾病，要想维 持治疗收益，必须确保持续性的某种干预措施。 此外，另一项周四发表的研究揭示了此类药物在缺乏专业指导下的潜在副作用。研究发现，自行购买药 物的用户面临营养不良和肌肉流失的风险，这表明在追求减重的过程中，部分患者可能正面临"用一种 健康问题通过另一种健康问题来替代"的风险。 一项基于广泛研究回顾的最新预测显示，停止服用抗肥胖药物的患者将在两年内恢复至原有体重，同时 失去药物带来的心脏健康、胆固醇水平和血压改善等主要收益。 格拉斯哥大学（University of Gl ...

By Puyaan Singh Jan 7 (Reuters) - Eli Lilly will buy autoimmune drug developer Ventyx Biosciences for $1.2 billion in cash, the ​companies said on Wednesday, marking the Zepbound maker's latest ‌push to expand beyond its blockbuster diabetes and weight-loss drugs. Ventyx is developing several ‌treatments, including oral therapies for inflammatory bowel diseases such as Crohn's and ulcerative colitis, besides drugs for immunity-related, cardiometabolic and neurodegenerative disorders. One of its drugs i ...

Key Points Pfizer has been making deals in recent years to enhance its long-term growth potential. Last month, it reached a GLP-1 licensing deal with a China-based drug company. Having more assets in its pipeline could make Pfizer an underrated growth stock now. 10 stocks we like better than Pfizer › Did you know that in just the past three years, healthcare giant Pfizer (NYSE: PFE) has lost approximately half its value? The stock surged during the pandemic as its COVID-19 vaccine and pill enabled ...

GM demonstrated strategic discipline by reducing EV investments amid changes in the regulatory environment and shifting consumer preferences, ending a $10 billion robotaxi program that will save $1 billion annually, and refocusing autonomous efforts on personal vehicles and Super Cruise.General Motors faced an unimaginable year of volatility after “Liberation Day” was announced in April. But under CEO Mary Barra’s stewardship, the auto company kept delivering, expected to lead U.S. sales among all manufactu ...

Key Points Eli Lilly briefly reached $1 trillion in market cap last year before retreating. The company has seen revenue soar in recent quarters thanks to its weight loss portfolio. 10 stocks we like better than Eli Lilly › Eli Lilly (NYSE: LLY) is close to doing something no other pharmaceutical company has ever done: reaching $1 trillion in market value. The company briefly touched that level in November but has since returned to about $960 billion. Why has the company been such a mover and shak ...

Core Insights - The medical sector is increasingly adopting artificial intelligence (AI), enhancing drug synthesis, device creation, and diagnostic accuracy [2][3] Group 1: Eli Lilly and Co. (LLY) - Eli Lilly focuses on cardiometabolic health, neuroscience, oncology, and immunology, which are high-growth areas with significant commercial potential [5] - Demand for LLY's GLP-1 drugs, Mounjaro and Zepbound, remains strong, contributing to robust sales in 2025 [6] - LLY is advancing its pipeline with an oral GLP-1 obesity pill, orforglipron, expected to launch next year [7] - Eli Lilly is collaborating with OpenAI for novel medicine discovery and invested $409 million in Genetic Leap for AI-driven drug discovery [7] - The company is building a supercomputer with NVIDIA to enhance its AI capabilities, with expected revenue and earnings growth rates of 22.3% and 41.3% respectively for the current year [8] - LLY has a return on equity (ROE) of 109.5%, significantly higher than the industry average of 37% [9] Group 2: Medtronic plc (MDT) - Medtronic is integrating AI into its solutions to improve patient care and operational efficiency, including an AI-powered surgical video management platform [10] - The GI Genius project enhances colorectal cancer detection, increasing survival rates by identifying polyps that may be missed [11] - Medtronic's partnerships leverage AI to optimize cardiac procedures and improve diagnostic precision, driving growth in the medtech sector [12] - The company has an expected revenue and earnings growth rate of 7.5% and 2.7% respectively for the current year [14] - MDT has a ROE of 14.9%, outperforming the industry average of -2.5% [14] Group 3: Intuitive Surgical Inc. (ISRG) - Intuitive Surgical is embedding AI into its robotic systems, providing objective performance indicators for surgeons [15] - The company is piloting telecollaboration for remote surgical support, enhancing training and decision-making [16] - ISRG's revenue and earnings growth rates are expected to be 14.3% and 11.1% respectively for the current year [19] - ISRG has a ROE of 15.1%, compared to the industry's ROE of -18.7% [19] Group 4: Regeneron Pharmaceuticals Inc. (REGN) - Regeneron utilizes AI and machine learning for drug target identification, clinical trial optimization, and precision medicine [20] - The company has seen revenue growth driven by strong performance from Dupixent and Libtayo, despite declining sales of Eylea [21] - REGN's expected revenue and earnings growth rates are 4.9% and -0.4% respectively for the current year [23] - REGN has a ROE of 13.8%, significantly higher than the industry's ROE of -65.41% [23] Group 5: Johnson & Johnson (JNJ) - Johnson & Johnson's MedTech division is focused on AI technologies for surgical robotics and digital surgery analytics [24] - The company has developed the Ottava robotic surgery platform and the Caresurgical/VELYS digital surgery systems, enhancing procedure planning [25] - JNJ has an expected revenue and earnings growth rate of 5% and 5.7% respectively for the current year [26] - JNJ has a ROE of 32.7%, compared to the industry's ROE of 37% [26]

Core Insights - The medical sector is rapidly adopting artificial intelligence (AI), significantly transforming diagnostics, treatment, and operational efficiency in 2024 [1] - AI-powered diagnostics have become central to enhancing accuracy and speed in medical practices [1] Group 1: AI Adoption in Healthcare - The healthcare sector is typically defensive, characterized by low-beta and dividend-paying stocks, but AI has turned several stocks into potential high-growth providers [2] - Key stocks benefiting from AI integration include Eli Lilly and Co. (LLY), Medtronic plc (MDT), Intuitive Surgical Inc. (ISRG), Regeneron Pharmaceuticals Inc. (REGN), and Johnson & Johnson (JNJ) [2] Group 2: Eli Lilly and Co. (LLY) - Eli Lilly focuses on cardiometabolic health, neuroscience, oncology, and immunology, which are high-growth areas with significant commercial potential [5] - Strong demand for LLY's GLP-1 drugs, Mounjaro and Zepbound, is driving top-line growth, supported by international market launches and increased production [6] - LLY is advancing its pipeline in obesity and diabetes, with an oral GLP-1 obesity pill expected to launch next year [7] - The company is collaborating with OpenAI and investing in AI-driven biotech initiatives, including a $409 million investment in Genetic Leap [9] - LLY has an expected revenue growth rate of 22.3% and earnings growth rate of 41.3% for the current year, with a beta of 0.35 and a dividend yield of 0.6% [9][10] Group 3: Medtronic plc (MDT) - Medtronic is integrating AI into its surgical systems and endoscopy to enhance patient care and operational efficiency [11] - The GI Genius project uses AI algorithms to detect colorectal polyps during colonoscopies, improving cancer survival rates [12] - MDT's partnerships leverage AI to optimize cardiac procedures and improve diagnostic precision, positioning the company for growth in medtech innovation [13] - Medtronic has an expected revenue growth rate of 7.5% and earnings growth rate of 2.7% for the current year, with a beta of 0.71 and a dividend yield of 3% [15] Group 4: Intuitive Surgical Inc. (ISRG) - Intuitive Surgical is embedding AI and digital tools into its robotic ecosystem, enhancing surgical performance metrics [16] - The company is piloting telecollaboration through Intuitive Telepresence, allowing remote surgical support [17] - ISRG has an expected revenue growth rate of 14.3% and earnings growth rate of 11.1% for the current year, with a beta of 0.39 and an ROE of 15.1% [20] Group 5: Regeneron Pharmaceuticals Inc. (REGN) - Regeneron utilizes AI and machine learning for drug target identification, clinical trial optimization, and precision medicine [21] - The company has seen revenue growth driven by strong performance from drugs like Eylea HD and Dupixent, despite declining sales of its lead drug [22] - REGN has an expected revenue growth rate of 4.9% and earnings growth rate of -0.4% for the current year, with a beta of 0.39 and a dividend yield of 0.5% [24] Group 6: Johnson & Johnson (JNJ) - Johnson & Johnson's MedTech division applies AI technologies for surgical robotics and digital surgery analytics [25] - The company has developed the Ottava robotic surgery platform and the Caresurgical/VELYS digital surgery systems, enhancing procedure planning and real-time data sharing [26] - JNJ has an expected revenue growth rate of 5% and earnings growth rate of 5.7% for the current year, with a beta of 0.34 and a dividend yield of 2.5% [27]